PL362698A1 - Nowe związki - Google Patents

Nowe związki

Info

Publication number
PL362698A1
PL362698A1 PL01362698A PL36269801A PL362698A1 PL 362698 A1 PL362698 A1 PL 362698A1 PL 01362698 A PL01362698 A PL 01362698A PL 36269801 A PL36269801 A PL 36269801A PL 362698 A1 PL362698 A1 PL 362698A1
Authority
PL
Poland
Prior art keywords
tumour
animal proteins
specific animal
polypeptides
polynucleotides
Prior art date
Application number
PL01362698A
Other languages
English (en)
Other versions
PL209127B1 (pl
Inventor
Teresa Elisa Virginia Cabezon-Silva
Jean-Pol Cassart
Thierry Coche
Swann Roman Jean-Thomas Gaulis
Y De Bassols Carlota Vinals
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0004269A external-priority patent/GB0004269D0/en
Priority claimed from GB0009905A external-priority patent/GB0009905D0/en
Priority claimed from GB0021080A external-priority patent/GB0021080D0/en
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of PL362698A1 publication Critical patent/PL362698A1/pl
Publication of PL209127B1 publication Critical patent/PL209127B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL362698A 2000-02-23 2001-02-16 Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka PL209127B1 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0004269A GB0004269D0 (en) 2000-02-23 2000-02-23 Novel compounds
GB0009905A GB0009905D0 (en) 2000-04-20 2000-04-20 Novel compounds
GB0021080A GB0021080D0 (en) 2000-08-25 2000-08-25 Novel compounds
PCT/EP2001/001779 WO2001062778A2 (en) 2000-02-23 2001-02-16 Tumour-specific animal proteins

Publications (2)

Publication Number Publication Date
PL362698A1 true PL362698A1 (pl) 2004-11-02
PL209127B1 PL209127B1 (pl) 2011-07-29

Family

ID=27255552

Family Applications (1)

Application Number Title Priority Date Filing Date
PL362698A PL209127B1 (pl) 2000-02-23 2001-02-16 Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka

Country Status (23)

Country Link
US (5) US20030157118A1 (pl)
EP (2) EP1265915B1 (pl)
JP (1) JP5502253B2 (pl)
KR (3) KR100848973B1 (pl)
CN (1) CN1254541C (pl)
AT (1) ATE487733T1 (pl)
AU (3) AU2001256156B2 (pl)
BR (1) BR0108654A (pl)
CA (1) CA2400842C (pl)
CY (2) CY1111156T1 (pl)
CZ (1) CZ303468B6 (pl)
DE (1) DE60143425D1 (pl)
DK (2) DK1650221T3 (pl)
ES (1) ES2389445T3 (pl)
HU (1) HUP0300054A3 (pl)
IL (2) IL151097A0 (pl)
MX (1) MXPA02008279A (pl)
NO (1) NO332141B1 (pl)
NZ (1) NZ520673A (pl)
PL (1) PL209127B1 (pl)
PT (2) PT1650221E (pl)
SI (2) SI1265915T1 (pl)
WO (1) WO2001062778A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1650221E (pt) * 2000-02-23 2012-09-05 Glaxosmithkline Biolog Sa Novos compostos
KR100831139B1 (ko) * 2000-10-18 2008-05-20 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
US8039602B2 (en) 2000-10-31 2011-10-18 Ryogen Llc Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
GB0100756D0 (en) 2001-01-11 2001-02-21 Powderject Res Ltd Needleless syringe
GB0111974D0 (en) * 2001-05-16 2001-07-04 Glaxosmithkline Biolog Sa Novel Compounds
AU2003243398A1 (en) * 2002-08-29 2004-03-19 Genentech, Inc. Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor
CN1310033C (zh) * 2004-03-23 2007-04-11 中国医学科学院肿瘤医院肿瘤研究所 一种检测血清蛋白指纹的新方法
EP2392675A1 (en) 2006-06-02 2011-12-07 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the IFNG gene
GB0708758D0 (en) 2007-05-04 2007-06-13 Powderject Res Ltd Particle cassettes and process thereof
UY31101A1 (es) 2007-05-24 2009-01-05 Glaxosmithkline Biologicals Sa Composición antigénica liofilizada
PE20120400A1 (es) * 2009-05-27 2012-05-04 Glaxosmithkline Biolog Sa Contrucciones de casb7439
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
WO2011066505A2 (en) * 2009-11-30 2011-06-03 Pathak Holdings Llc Methods and compositions for filling fleshy fruits and vegetables
US10047116B2 (en) * 2011-10-03 2018-08-14 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
GB201520592D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
RS65430B1 (sr) 2016-03-16 2024-05-31 Amal Therapeutics Sa Kombinacija modulatora imunološke kontrolne tačke i kompleksa koji sadrži peptid koji prodire u ćeliju, teret i tlr peptidni agonist za primenu u medicini
KR102879364B1 (ko) 2016-09-21 2025-11-04 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
US10422675B2 (en) 2017-06-09 2019-09-24 Aps Technology, Inc. System and method for monitoring mud flow in a component of drilling system

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE10399031I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
ES2084698T5 (es) 1989-05-04 2005-03-01 Southern Research Institute Procedimiento de encapsulacion.
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
KR920007887B1 (ko) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
JPH05503841A (ja) 1989-11-16 1993-06-24 デューク ユニバーシティ 動物組織細胞の微片仲介トランスフォーメーション
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
GB9022190D0 (en) 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
WO1993015763A1 (en) * 1992-02-18 1993-08-19 Smithkline Beecham Corporation Vaccinal polypeptides
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DE69418699T2 (de) 1993-01-11 1999-09-30 Dana-Farber Cancer Institute, Boston Induktion der antworten zytotoxischer t-lymphozyten
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
US5747292A (en) 1993-04-06 1998-05-05 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
EP0705341A1 (en) 1993-06-07 1996-04-10 Amgen Inc. Hybrid receptor molecules
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0679716A4 (en) 1993-11-12 1999-06-09 Kenichi Matsubara GENE SIGNATURE.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK1293559T3 (da) 1994-01-21 2005-11-28 Powderject Vaccines Inc Gasdrevet genindförselsinstrument
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
WO1997028820A1 (en) * 1996-02-09 1997-08-14 Smithkline Beecham Biologicals S.A. Vaccines against varicella zoster virus gene 63 product
US5776683A (en) 1996-07-11 1998-07-07 California Pacific Medical Center Methods for identifying genes amplified in cancer cells
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
CN1227360C (zh) * 1998-02-05 2005-11-16 史密丝克莱恩比彻姆生物有限公司 Mage家族肿瘤相关抗原衍生物及其编码核酸序列
CA2320488C (en) 1998-02-12 2007-03-06 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
KR20010041629A (ko) 1998-03-09 2001-05-25 장 스테판느 혼합 백신 조성물
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
PT1104306E (pt) 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
US6087168A (en) * 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
DE60031383T2 (de) * 1999-03-11 2007-11-15 Glaxosmithkline Biologicals S.A. Verwendung von casb618 polynucleotide und polypeptide
WO2001002828A2 (en) 1999-07-07 2001-01-11 Tularik Inc. Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
US7811574B2 (en) * 2000-02-23 2010-10-12 Glaxosmithkline Biologicals S.A. Tumour-specific animal proteins
PT1650221E (pt) * 2000-02-23 2012-09-05 Glaxosmithkline Biolog Sa Novos compostos
US8039602B2 (en) * 2000-10-31 2011-10-18 Ryogen Llc Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
AU2003243398A1 (en) 2002-08-29 2004-03-19 Genentech, Inc. Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor
PE20120400A1 (es) 2009-05-27 2012-05-04 Glaxosmithkline Biolog Sa Contrucciones de casb7439

Also Published As

Publication number Publication date
NO20024002D0 (no) 2002-08-22
IL151097A (en) 2012-05-31
CZ303468B6 (cs) 2012-10-03
US20060171953A1 (en) 2006-08-03
EP1650221A2 (en) 2006-04-26
SI1265915T1 (sl) 2011-02-28
US20030157118A1 (en) 2003-08-21
CN1254541C (zh) 2006-05-03
KR20090085697A (ko) 2009-08-07
PT1265915E (pt) 2011-02-07
NO332141B1 (no) 2012-07-02
NO20024002L (no) 2002-10-22
EP1265915A2 (en) 2002-12-18
KR20020079887A (ko) 2002-10-19
NZ520673A (en) 2004-09-24
HUP0300054A1 (hu) 2003-05-28
AU5615601A (en) 2001-09-03
HUP0300054A3 (en) 2012-09-28
DE60143425D1 (de) 2010-12-23
DK1650221T3 (da) 2012-09-03
CZ20022874A3 (cs) 2003-02-12
US20120244175A1 (en) 2012-09-27
AU2006201042B2 (en) 2009-10-08
WO2001062778A2 (en) 2001-08-30
IL151097A0 (en) 2003-04-10
US7803379B2 (en) 2010-09-28
CN1426421A (zh) 2003-06-25
HK1093513A1 (en) 2007-03-02
JP2003530088A (ja) 2003-10-14
CY1111156T1 (el) 2015-06-11
JP5502253B2 (ja) 2014-05-28
CA2400842C (en) 2013-01-15
KR20080029007A (ko) 2008-04-02
DK1265915T3 (da) 2011-02-14
ATE487733T1 (de) 2010-11-15
PT1650221E (pt) 2012-09-05
BR0108654A (pt) 2003-04-29
KR100848973B1 (ko) 2008-07-30
HK1052710A1 (en) 2003-09-26
US20100291121A1 (en) 2010-11-18
MXPA02008279A (es) 2002-11-29
SI1650221T1 (sl) 2012-09-28
EP1650221A3 (en) 2006-12-20
US8535690B2 (en) 2013-09-17
PL209127B1 (pl) 2011-07-29
WO2001062778A3 (en) 2002-04-04
KR100919916B1 (ko) 2009-10-07
EP1650221B1 (en) 2012-06-27
CY1113109T1 (el) 2016-04-13
EP1265915B1 (en) 2010-11-10
ES2389445T3 (es) 2012-10-26
AU2001256156B2 (en) 2006-01-05
CA2400842A1 (en) 2001-08-30
AU2006201042A1 (en) 2006-03-30
US8207123B2 (en) 2012-06-26
US20110052615A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
IL151097A0 (en) Tumour-specific animal proteins
PL354143A1 (pl) Nowe zastosowaniaNowe zastosowania
IL153996A0 (en) Polypeptides containing at least a portion of an ovarian carcinoma protein, polynucleotides encoding the same and pharmaceutical compositions containing the same
NZ513838A (en) Novel compounds
DK1163343T3 (da) Neisseria meningitidis antigene polypeptider, tilsvarende polynukleotider og beskyttende antistoffer
WO2000058460A3 (en) Casb619 involved in colon cancers
ATE281524T1 (de) Moraxella catarrhalis pilq proteine
PL345193A1 (en) Basb027 proteins and genes from moraxella catarrhalis
WO2001023417A3 (en) Human tumor-associated lak-4p related polynucleotides and polypeptides and their uses
WO2000043509A3 (en) Polynucleotides and their applications in diagnostics
PT1204752E (pt) Polipéptidos imunogénicos derivados de moraxella catarrhalis e suas utilizações
CY1108790T1 (el) Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου
WO2002024729A3 (en) Haemophilus influenzae basb202 polypeptide, production, vaccine and diagnostic use
ATE515511T1 (de) Nicht-typisierbare haemophilus influenzae basb201 polypeptide und polynukleotide und deren verwendungen
WO2001034795A3 (en) Casb7435 polypeptide, nucleic acid encoding it, and their uses in treatment and diagnosis
DE60019614D1 (de) Moraxella catarrhalis antigen basb117
WO2002032945A3 (en) Haemophilus influenzae basb206 gene and protein
DE60019613D1 (de) Moraxella catarrhalis antigen basb120
WO2001075001A3 (en) A novel polypeptide, cyclic adenosine 9-dependant human protein kinase and the polynucleotide encoding the polypeptide
WO2002079237A3 (en) Non-typeable haemophilus influenzae immunogenic polypeptides and use thereof
WO2002088360A3 (en) Haemophilus influenzae antigens

Legal Events

Date Code Title Description
RECP Rectifications of patent specification